Literature DB >> 19830402

[What is most important is what comes across : Urological guidelines from the target group's point of view].

J Busch1, C Röllig, L Weissbach, C Kempkensteffen, S Hinz, C Jahnke, M Schostak, M Lein, S Weikert, C Stephan, S Deger, G Ollenschläger, K Miller, M Schrader.   

Abstract

BACKGROUND: Guidelines are developed to improve the quality of patient care. The effect of German urologic guidelines has not been evaluated so far. Therefore, we aimed to systematically investigate the acceptance, use, and quality of the published guidelines from a user's perspective.
METHODS: A link to an online questionnaire concerning use and barriers to the application of guidelines was distributed via e-mail by the German Society of Urology (DGU). German urologists' opinions on differences in national guideline quality were evaluated regarding prostate cancer (PCA), bladder cancer, germ cell tumors (GCT), renal cell carcinomas, and erectile dysfunction.
RESULTS: Four hundred sixty-seven German urologists participated. More than 90% of the participants considered guidelines to be helpful. The Internet as the main tool for guideline distribution was favored by 28.4%, followed by publication in Urologe A. The main barrier to guideline usage was attributed to the lack of up-to date clinical data. Guidelines for GCT scored best in all quality categories and reached the highest level of use (65.8%), and 40.5% of participating urologists considered the additional establishment of comprehensive care centers for GCT as more effective for quality improvement than guideline development alone. For the other urologic tumors, especially PCA, guideline development was favored as a tool for quality improvement.
CONCLUSION: More than 90% of participating urologists accept clinical guidelines as useful instruments in clinical practice and for therapeutic decisions. Our results should be integrated into guideline dissemination and implementation strategies in order to achieve a higher degree of treatment conformation to guidelines.

Entities:  

Mesh:

Year:  2010        PMID: 19830402     DOI: 10.1007/s00120-009-2134-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  9 in total

1.  [Guidelines for therapy of testicular tumors. German Society of Urology].

Authors: 
Journal:  Urologe A       Date:  1999-03       Impact factor: 0.639

2.  Paying physicians for high-quality care.

Authors:  Arnold M Epstein; Thomas H Lee; Mary Beth Hamel
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

3.  The quality of health care delivered to adults in the United States.

Authors:  Elizabeth A McGlynn; Steven M Asch; John Adams; Joan Keesey; Jennifer Hicks; Alison DeCristofaro; Eve A Kerr
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

4.  ["Second opinion centers". Approach for improving the quality of treatment for testicular tumors].

Authors:  M Schrader; M Hartmann; S Krege; K Miller; L Weissbach
Journal:  Urologe A       Date:  2006-04       Impact factor: 0.639

Review 5.  Assessing the quality of prostate cancer care.

Authors:  David F Penson
Journal:  Curr Opin Urol       Date:  2008-05       Impact factor: 2.309

6.  Quality of prostate carcinoma care in a statewide public assistance program.

Authors:  Tracey L Krupski; Jonathan Bergman; Lorna Kwan; Mark S Litwin
Journal:  Cancer       Date:  2005-09-01       Impact factor: 6.860

7.  Measuring the quality of care for localized prostate cancer.

Authors:  David C Miller; James E Montie; John T Wei
Journal:  J Urol       Date:  2005-08       Impact factor: 7.450

8.  Use of quality indicators to evaluate the care of patients with localized prostate carcinoma.

Authors:  David C Miller; Mark S Litwin; Martin G Sanda; James E Montie; Rodney L Dunn; Jennifer Resh; Howard Sandler; John T Wei
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

9.  Effects of two guideline implementation strategies on patient outcomes in primary care: a cluster randomized controlled trial.

Authors:  Annette Becker; Corinna Leonhardt; Michael M Kochen; Stefan Keller; Karl Wegscheider; Erika Baum; Norbert Donner-Banzhoff; Michael Pfingsten; Jan Hildebrandt; Heinz-Dieter Basler; Jean F Chenot
Journal:  Spine (Phila Pa 1976)       Date:  2008-03-01       Impact factor: 3.468

  9 in total
  7 in total

1.  [Methodology and process of developing the S3 guideline for prostate cancer].

Authors:  M Nothacker; C Röllig; A Wöckel; I Kopp; G Ollenschläger; S Weinbrenner
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

2.  [Guidelines: reality and quality].

Authors:  S Rogenhofer; F Zengerling; M Schrader; S C Müller
Journal:  Urologe A       Date:  2012-08       Impact factor: 0.639

3.  [Implementation of the S3 prostate cancer guideline in daily clinical practice: results of a survey among urologists].

Authors:  M Fröhner; C Khan; R Koch; S G Schorr; M Wirth
Journal:  Urologe A       Date:  2014-10       Impact factor: 0.639

4.  [Guideline adherence - is more always better?].

Authors:  M J Nothacker
Journal:  Urologe A       Date:  2016-09       Impact factor: 0.639

5.  [German national second-opinion network for testicular cancer and penile carcinoma : Two sources for evidence-based information].

Authors:  M Schrader; F Zengerling; O W Hakenberg; C Protzel
Journal:  Urologe A       Date:  2016-09       Impact factor: 0.639

6.  [Validation of pre-cystectomy nomograms for the prediction of locally advanced urothelial bladder cancer in a multicentre study: are we able to adequately predict locally advanced tumour stages before surgery?].

Authors:  M May; M Burger; S Brookman-May; W Otto; J Peter; O Rud; H-M Fritsche; C Bolenz; L Trojan; E Herrmann; M S Michel; C Wülfing; R Moritz; A Tiemann; S C Müller; J Ellinger; A Buchner; C G Stief; D Tilki; W F Wieland; C Gilfrich; T Höfner; M Hohenfellner; A Haferkamp; J Roigas; P Bretschneider-Ehrenberg; O Müller; M Zacharias; S Gunia; P J Bastian
Journal:  Urologe A       Date:  2011-06       Impact factor: 0.639

7.  [Certified prostate cancer centers and second opinion centers for testicular cancer: successful models of uro-oncology cancer care].

Authors:  J E Gschwend; P Albers; M Schrader
Journal:  Urologe A       Date:  2011-08       Impact factor: 0.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.